Team

David Lindenbach, PhD
Research Associate

Credentials:
Ph.D. (State University of New York at Binghamton)


Contact:
Room 4D56, 3280 Hospital Drive NW Calgary AB T2N 4Z6 
☎   +1 (403) 210-6223
📧 [email protected]

I began my career as a social worker serving marginalized communities of homeless and mentally ill youth and adults. I wanted to understand more about how the brains of my clients were different from others in society, so I pursued a PhD in Behavioral Neuroscience. Along the way, I acquired skills in probing the pathophysiology and treatment of neurological and psychiatric disorders. 

In my role within Dr. Arnold's laboratory, I am trying to fuse these elements of my career for an ambitious project that seeks to understand how abuse and neglect alters the trajectory of a child's development. This longitudinal cohort design tries to capture periodic snapshots of a child in time--examining life events, social status, brain function and gene regulation--to predict risk and resilience to the traumatic effects of abuse and neglect. We are also examining how targeted therapeutic interventions can mitigate the harm caused by abuse or neglect and improve outcomes in adolescence and early adulthood.

Publications: 
- Lindenbach, D., Seamans, J.K. & Phillips, A.G. 2019. Activation of the ventral subiculum reinvigorates behavior after failure to achieve a goal: implications for dopaminergic modulation of motivational processes. Behavioral Brain Research 356, 266-270.
- Ferland, J-M., Hynes, T., Hounjet, C., Lindenbach, D., Vonder Haar, C., Adams, W., Phillips, A. & Winstanley, C. 2019. Prior exposure to salient win-paired cues enhances cocaine-induced risky decision making and suppresses dopamine efflux in the nucleus accumbens: support for the reward deficiency hypothesis of addiction. The Journal of Neuroscience 39, 1842-1854.
- Lindenbach, D., Das, B., Conti, M.M., Meadows, S.M., Dutta, A.K. & Bishop, C. 2017. D-512, a novel dopamine D2 / D3 receptor agonist, demonstrates superior anti-parkinsonian efficacy over ropinirole in Parkinsonian rats. British Journal of Pharmacology 174, 3058-3071.
- Lindenbach, D., Conti, M.M., Ostock, C.Y., George, J.A., Goldenberg, A.A., Melikhov-Sosin, M., Nuss, E.N. & Bishop, C. 2016. The role of primary motor cortex (M1) glutamate and GABA signaling in L-DOPA-induced dyskinesia in Parkinsonian rats. The Journal of Neuroscience 36:9873-9887.
- Conti, M.M., Meadows, S., Melikhov-Sosin, M., Lindenbach, D., Hallmark, J., Werner, D.F. & Bishop, C. 2016. Monoamine transporter contributions to L-DOPA effects in hemi-parkinsonian rats. Neuropharmacology 110:125-134.
- Conti, M.M., Goldenberg, A.A., Kuberka, A., Mohamed, M., Eisa, S., Lindenbach, D., & Bishop, C. 2016. Effect of tricyclic antidepressants on L-DOPA-induced dyskinesia and motor improvement in hemi-Parkinsonian rats. Pharmacology, Biochemistry and Behavior 142, 64-71.
- Lindenbach, D., Conti, M.M., Ostock, C.Y., Dupre, K.B. & Bishop, C. 2015. Alterations in primary motor cortex neurotransmission and gene expression in a rat model of Parkinson’s disease and drug-induced dyskinesia. Neuroscience310, 12-26.
- Bhide, N., Lindenbach, D., Barnum, C.J., George, J.A., Surrena, M.A. & Bishop, C. 2015. Effects of the beta-adrenergic receptor antagonist Propranolol on dyskinesia and L-DOPA-induced striatal DA efflux in the hemi-parkinsonian rat.Journal of Neurochemistry 134, 222-232.
- Lindenbach, D., Palumbo, N., Ostock, C.Y., Vilceus, N., Conti, M.M. & Bishop, C. 2015. Side-effect profile of serotonergic treatments for Parkinson’s disease and L-DOPA-induced dyskinesia in rats. British Journal of Pharmacology 172, 119-130.
- Ostock, C.Y., Lindenbach, D., Goldenberg, A.A., Kampton, E. & Bishop, C. 2014. Effects of noradrenergic denervation by anti-DBH-saporin on behavioral responsivity to L-DOPA in the hemi-parkinsonian rat. Behavioral Brain Research 270, 75-85.
- Conti, M.C., Ostock, C.Y., Lindenbach, D., Goldenberg, A.A., Kampton, E., Dell’isola, R., Katzman, A. & Bishop, C. 2014.Effects of prolonged selective serotonin reuptake inhibition on the development and expression of L-DOPA-induced dyskinesia in hemi-parkinsonian rats. Neuropharmacology 77, 1-8.
- Lindenbach, D. & Bishop, C. 2013. Critical involvement of the motor cortex in the pathophysiology and treatment of Parkinson’s disease. Neuroscience and Biobehavioral Reviews 37, 2737-2750.
- Lindenbach, D., Dupre, K.B., Eskow Jaunarajs, K.L., Ostock, C.Y., Goldenberg, A.A. & Bishop, C. 2013. Effects of 5-HT1A receptor stimulation on striatal and cortical M1 pERK induction by L-DOPA and a D1 receptor agonist in a rat model of Parkinson’s disease. Brain Research 1537, 327-339.
​- Bhide, N., Lindenbach, D., Surrena, M.A., Goldenberg, A.A., Bishop, C., Berger, S.P. & Paquette, M.A. 2013. BMY-14802, a 5-HT1A receptor agonist, attenuates L-DOPA and DA agonist-induced dyskinesia without affecting L-DOPA efficacy.Psychopharmacology 227, 533-44.
- Barnum, C.J., Bhide, N., Lindenbach, D., Surrena, M.A., Goldenberg, A.A., Tignor, S., Klioueva, A., Walters, H. & Bishop, C. 2012. Effects of noradrenergic deneveration on L-DOPA-induced dyskinesia and it’s treatment by α- and β-adrenergic receptor antagonists in hemiparkinsonian rats. Pharmacology Biochemistry and Behavior 100, 607-615.
- Lindenbach, D., Ostock, C.Y., Eskow Jaunarajs, K.L., Dupre, K.B., Barnum, C.J., Bhide, N. & Bishop, C. 2011. Behavioral and cellular modulation of L-DOPA-induced dyskinesia by β-adrenoceptor blockade in the 6-hydroxydopamine-lesioned rat. 
Journal of Pharmacology and Experimental Therapeutics 337, 355-365.